Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0EJPKN
ADC Name	HuXBR1-402-G5-PNU
Synonyms	HuXBR1-402-G5-PNU (NBE-Therapeutics/Ohio State University/The Scripps Research Institute); huXBR1-402-PNU; huXBR1 402 PNU Click to Show/Hide
Organization	NBE-Therapeutics AG; The Scripps Research Institute; The Ohio State University
Drug Status	Clinical candidate
Indication	In total 3 Indication(s) Acute lymphoblastic leukemia [ICD11:2B33] Clinical candidate B-cell lymphoma [ICD11:2A86] Clinical candidate Mantle cell lymphoma [ICD11:2A85] Clinical candidate
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Anti-ROR1 mAb huXBR1-402		Antibody Info
Antigen Name	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)		Antigen Info
Payload Name	PNU-159682		Payload Info
Therapeutic Target	DNA topoisomerase 2-alpha (TOP2A)		Target Info
Linker Name	Gly5-FITC		Linker Info
Conjugate Type	Sortase-mediated antibody conjugation (SMAC) technology.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	1.27	ng/mL	Kasumi-2 cells	Childhood B acute lymphoblastic leukemia
Half Maximal Inhibitory Concentration (IC50)	75.68	ng/mL	697 cells	Childhood B acute lymphoblastic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.27 ng/mL	Positive ROR1 expression (ROR1+++/++)
Method Description	Cell lines obtained from ATCC were serum starved for 16 hours and reintroduced to full serum media supplemented huXBR1-402-G5-PNU for 72 hours. Viability was measured by using MTS assays, and relative light unit (RLU) values for each dose were generated after 72 hours of treatment in 2 independent experiments.
In Vitro Model	Childhood B acute lymphoblastic leukemia	Kasumi-2 cells		CVCL_0590
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	75.68 ng/mL	Positive ROR1 expression (ROR1+++/++)
Method Description	Cell lines obtained from ATCC were serum starved for 16 hours and reintroduced to full serum media supplemented huXBR1-402-G5-PNU for 72 hours. Viability was measured by using MTS assays, and relative light unit (RLU) values for each dose were generated after 72 hours of treatment in 2 independent experiments.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079

References

Ref 1	The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Adv. 2021 Aug 24;5(16):3152-3162.